Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
Impact
This resolution comes at a time when chemical abortions account for over half of all abortions performed in the United States. The FDA's approval of a new generic version of mifepristone, a common medication used in these procedures, has raised further questions about safety and availability. Advocates of the resolution assert that the increased access to chemical abortion drugs, coupled with a lack of stringent regulations on their use, could lead to situations where these drugs are misused, potentially causing harm to women and girls.
Summary
House Resolution 803 urges the Director of the Food and Drug Administration (FDA) to reevaluate the safety of all chemical abortion drugs, specifically in light of recent independent studies. The resolution highlights concerns regarding the expansion of access to these drugs, which have seen significant regulatory easing under both the Obama and Biden administrations. The intent is to ensure that the safety and efficacy of these medications are reassessed, especially given the alarming statistics presented about their complication rates.
Contention
Notably, there is a significant divergence of opinion surrounding this resolution. Supporters argue that it is necessary to protect women’s health and ensure informed decision-making, while opponents claim that such a reevaluation may infringe on reproductive rights and access to critical healthcare services. Additionally, concerns have been voiced about the ethical implications of public funding for providers who prescribe these medications, further complicating the discussion.
Final_thoughts
In essence, HR803 serves as both a call to action for regulatory scrutiny and a point of contention among lawmakers, reflecting the broader national debate over reproductive rights and healthcare access. It raises fundamental questions about the balance between ensuring safety and preserving access to essential healthcare services.
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
An Act to Make Manufacturers Responsible for Proper Disposal of Abortion Drugs and Require a Health Care Provider to Be Physically Present During a Chemical Abortion
A bill for an act relating to abortions including informed consent, dispensing abortion-inducing drugs, and reporting abortion-inducing drug complications.
To provide the Food and Drug Administration needed authorities to carry out its regulatory mission with respect to human foods, to provide additional resources and authorities with respect to human foods research, and for other purposes.
A bill for an act relating to abortions including definitions, informed consent, dispensing of abortion-inducing drugs, and other abortion-related provisions. (Formerly HF 2563, HSB 704.) Effective date: 07/01/2026.